GSK could not disprove communication of congenital anomalies with Zofran's reception

The British pharmaceutical companies GlaxoSmithKline was not succeeded to achieve the termination of judicial proceedings in claims Americans who during pregnancy accepted an antiemetic preparation Zofran (ondansetron) then at their children congenital anomalies developed. Hundred women accused the producer that he did not bring the corresponding caution in Zofran's instruction. Court rejected the petition of the respondent...